Citations

Clear

400 citation(s) found for "Berry, DA".

Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent Clostridioides difficile infection
Berry, Parul , Khanna, Sahil

Mayo Clinic

Future Microbiology | September 25, 2024 | Volume: 19 | Issue: 18 | Pages: 1519-1528

10.1080/17460913.2024.2403892 | PMID 39320321 Get It

Outcomes of Obese Patients Undergoing Primary Total Knee Arthroplasty
Uvodich, Mason E. , Dugdale, Evan M. , Pagnano, Mark W. , Berry, Daniel J. , Abdel, Matthew P. , Bedard, Nicholas A. , Abdel, Matthew P , Berry, Daniel J , Bedard, Nicholas A

Mayo Clinic

Journal of Bone and Joint Surgery | September 24, 2024 | Volume: 106 | Issue: 21 | Pages: 1963-1970

10.2106/jbjs.23.01413 | PMID 39316660 Get It

Background: The rates of obesity among patients undergoing total knee arthroplasty (TKA) have substantially increased. In addition, obesity is a well-established risk factor for complications after TKA. The purpose of this study was to analyze trends in body mass index (BMI) and complication risk among obese patients undergoing primary TKA treated at a single institution over 3 decades. Methods: Utilizing an institutional total joint registry, 13,919 primary TKAs performed to treat osteoarthritis between 1990 and 2019 were identified. Patients were stratified by BMI according to the World Health Organization (WHO) classification into 3 groups: non-obese (BMI, <30 kg/m 2 ), WHO Class-I and II obese (BMI, 30 to 39.9 kg/m 2 ), and WHO Class-III obese (BMI, ≥40 kg/m 2 ). Trends in BMI and survivorship free from reoperation, revision, and periprosthetic joint infection (PJI) were analyzed over time while controlling for age, sex, and the Charlson Comorbidity Index. Results: Over the study period, there was a 90% increase in the prevalence of Class-II obesity (13% to 25%) and a 300% increase in Class-III obesity (3% to 12%). Analysis of the entire cohort demonstrated a decrease in the 2-year risk of any reoperation, any revision, and PJI (p < 0.05 for all) with time. The risk decreased significantly over time for non-obese patients for any reoperation (p = 0.029) and any revision (p = 0.004) and for Class-III obese patients for any reoperation (p = 0.038) and any revision (p = 0.012), but it remained stable for Class-I and II obese patients. The risk of PJI decreased from 1990 to 2019 for non-obese patients (p = 0.005), but there were no significant changes in PJI risk for any obesity group. Conclusions: Despite increasing rates of obesity among our patients who underwent TKA, we observed decreasing risks of reoperation, revision, and PJI over time. The risks of reoperation and revision declined among non-obese patients, remained stable for Class-I and II obese patients, and declined for Class-III obese patients. The PJI risk declined for non-obese patients over the study period, but no such decline occurred for any category of obesity. Despite the decreasing risks of reoperation and revision, further work is needed to improve PJI risk in obese patients. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, Howard , Cummings, Jeffrey L., Boxer, Adam L., Staffaroni, Adam M. , Knopman, David S., Territo, Paul R. , Arnold, Steven E. , Boeve, Bradley F., Dacks, Penny A. , Diaz, Kristophe , Ewen, Colin, González, María Isabel , Harris, Glenn A., Hoffman, Beth J., Martinez, Terina N. , Nisenbaum, Laura K., Palma, Jose‐Alberto , Quintana, Melanie , Rabinovici, Gil D. , Rohrer, Jonathan D. , Rosen, Howard J., Troyer, Matthew D. , Kim, Doo Yeon , Tanzi, Rudolph E. , Zetterberg, Henrik, Ziogas, Nick, May, Patrick C. , Rommel, Amy, Feldman, Howard H , Palma, Jose-Alberto , Rohrer, Jonathan D , Rabinovici, Gil D , Dacks, Penny , Boxer, Adam L. , Knopman, David S. , Rizzo, Stacey J. Sukoff , Ballard, Clive , Beher, Dirk , Boeve, Bradley F. , Fiske, Brian , McDade, Eric , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | September 24, 2024 | Volume: 20 | Issue: 11 | Pages: 8129-8152

10.1002/alz.14250 | PMID 39316411 Get It

AbstractThe tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early‐phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early‐phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need.Highlights Experts provided a framework to translate therapeutics (discovery to clinical trials). Experts focused on the “5 Rights” (target, drug, biomarker, participants, trial). Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics) Tau therapeutics are being tested in Alzheimer's disease; primary tauopathies have a large unmet need.
Esophageal Expert Development of a Preliminary Question Prompt List for Adults With Eosinophilic Esophagitis: A Modified Delphi Study
Achalu, Sudharshan, Berry, Rani , Joseph, Abel , Bhargava, Meera , Fernandez‐Becker, Nielsen , Chang, Joy W. , Dellon, Evan S. , Hirano, Ikuo , Horsley‐Silva, Jennifer L. , Leiman, David A. , Lynch, Kristle L. , Peterson, Kathryn , Kamal, A. N. , Horsley-Silva, Jennifer, Bredenoord, Albert J. , Falk, Gary W. , Kamal, Afrin N.

Mayo Clinic

Journal of Clinical Gastroenterology | September 23, 2024 | Volume: 59 | Issue: 6 | Pages: 537-541

10.1097/mcg.0000000000002066 | PMID 39312545 Get It

Background: Question prompt lists (QPLs) are structured sets of disease-specific questions intended to encourage question-asking by patients and enhance patient-physician communication. To date, an EoE-specific QPL has not been developed for EoE patients. Aim: To develop a preliminary QPL specific to adults with EoE by incorporating input from international esophageal experts. Methods: Sixteen experts were invited to generate QPL content through a modified Delphi (RAND/University of California, Los Angeles, CA) method consisting of 2 rounds of independent ratings. In round 1, experts provided 5 answers to the prompts “what general questions should patients ask when being seen for EoE?” and “what questions do I not hear patients asking but given my experience, I believe they should be asking?” In round 2, experts rated each question on a 5-point Likert scale, and responses rated as “essential” or “important” (determined by an a priori median threshold of ≥ 4.0) were accepted for the EoE QPL. Results: Ten esophageal experts participated in both rounds. Round 1 generated 100 questions. Questions were combined and modified to reduce redundancy, yielding 57 questions. After round 2, 51 questions (85%) were accepted for inclusion (median value ≥ 4.0) in the final QPL. Questions were then divided into 4 themes based on disease domains: (1) “What is EoE?,” (2) “Treatment Options,” (3) “Follow-up Surveillance and Long-term Risks,” and (4) “Allergy and Genetic Testing.” The largest number of questions covered was “What is EoE?” (16/51 or 31%). Questions with the highest agreement median (5.0) included examples such as “what should I do if I get a food impaction?” and “what are the treatment options?” Conclusion: This is the first preliminary EoE QPL developed in the field of medicine. We hope implementation enhances effective patient-physician communication by encouraging patients to ask relevant questions that experts prioritized. Future studies will aim to modify this communication tool by incorporating patient perspectives
Patient Education: Hepatitis C Infection
Khanna, Sahil , Berry, Parul

Mayo Clinic

Journal of Gastrointestinal Infections | September 18, 2024 | Volume: 14 | Issue: 02 | Pages: 073-075

10.1055/s-0044-1790591 Get It

Incidence and Predictors of Stroke in Australian Adults With Congenital Heart Disease (2000–2017)
Sodhi‐Berry, Nita , Burchill, Luke J. , Nedkoff, Lee , Katzenellenbogen, Judith , Kleinig, Timothy J , Nedkoff, Lee , Katzenellenbogen, Judith M , Burchill, Luke J , Kleinig, Timothy

Mayo Clinic

Journal of the American Heart Association | August 27, 2024 | Volume: 13 | Issue: 17 | Pages: No page available

10.1161/jaha.123.034057 | PMID 39190566 Get It

Background Adults with congenital heart disease (CHD) are at increased risk of stroke but high‐quality population level data on stroke incidence in these patients are scant. Methods and Results A retrospective whole‐population Western Australian cohort of adult patients with CHD aged 18 to 64 years was created and followed from January 2000 to December 2017 using linked hospital data. Stroke incidence rates within the adult cohort with CHD were calculated and compared with the general population via direct standardization. A nested case–control design assessed predictors of ischemic and hemorrhagic stroke within the cohort. Among 7916 adults with CHD, 249 (3.1%) incident strokes occurred at a median age of 47 years; 186 (2.3%) ischemic, 33 (0.4%) hemorrhagic and 30 (0.4%) unspecified strokes. Ischemic and hemorrhagic stroke incidence was, respectively, 9 and 3 times higher in adults with CHD than the general population. Absolute risk was low with annual rates of 0.26% (ischemic) and 0.05% (hemorrhagic). Highest rates were observed in adults with shunt and left‐sided lesions. Predictors of ischemic stroke in adults with CHD included recent cardiac surgery, left‐sided valve repair/replacements, shunt lesions, and traditional risk factors (hypertension, infective endocarditis, peripheral vascular disease, and tobacco use). Mental health disorders and increasing Charlson's comorbidity scores were strongly associated with higher risk of ischemic and hemorrhagic stroke. The CHA 2 DS 2 VASc score was associated with ischemic stroke incidence. Conclusions This study provides the first population‐based stroke incidence estimates for adults with CHD in Australia, showing elevated stroke risk across different CHD lesions. It highlights the potential clinical importance of managing comorbidities, especially mental health.
TOTAL HIP ARTHROPLASTY IN PATIENTS WITH ANGULAR PROXIMAL FEMORAL DEFORMITIES
Dagneaux, Louis , Lewallen, David G. , Trousdale, R T, Abdel, Matthew P. , Sierra, Rafael J. , Berry, Daniel J.

Mayo Clinic

Orthopaedic Proceedings | August 19, 2024 | Volume: 106-B | Issue: SUPP_16 | Pages: 24-24

10.1302/1358-992x.2024.16.024 Get It

Angular proximal femoral deformities increase the technical complexity of primary total hip arthroplasties (THAs). The goals were to determine the long-term implant survivorship, risk factors, complications, and clinical outcomes of contemporary primary THAs in this difficult cohort.Our institutional total joint registry was used to identify 119 primary THAs performed in 109 patients with an angular proximal femoral deformity between 1997 and 2017. The deformity was related to previous femoral osteotomy in 85%, and developmental or metabolic disorders in 15%. 53% had a predominantly varus angular deformity. The mean age was 44 years, mean BMI was 29 kg/m2, and 59% were female. An uncemented metaphyseal fixation stem was used in 30%, an uncemented diaphyseal fixation stem in 28%, an uncemented modular body stem with metaphyseal fixation sleeve in 24%, and a cemented stem in 18%. Simultaneous corrective femoral osteotomy was performed in 18%. Kaplan-Meier survivorships and Harris hip scores were reported. Mean follow-up was 8 years.The 10-year survivorships free of femoral loosening, aseptic femoral revision, any revision, and any reoperation were 95%, 93%, 90% and 88%, respectively. Revisions occurred in 13 hips for: aseptic femoral component loosening (3), stem fracture (2), dislocation (2), aseptic acetabular loosening (2), polyethylene liner exchange (2), and infection (2). Preoperative varus angular deformities were associated with a higher risk of any revision (HR 10, p=0.03), and simultaneous osteotomies with a higher risk of any reoperation (HR 3.6, p=0.02). Mean Harris hip scores improved from 52 preoperatively to 82 at 10 years (p<0.001).In the largest series to date of primary THAs in patients with angular proximal femoral deformities, we found a good 10-year survivorship free from any revision. Varus angular deformities, particularly those treated with a simultaneous osteotomy due to the magnitude or location of the deformity, had a higher reoperation rate.Keywords: Proximal femoral deformity; dysplasia; femoral osteotomy; survivorship; revisionLevel of evidence: Level III, comparative retrospective cohort
Subclinical aortic inflammation in patients with polymyalgia rheumatica
Kaymakci, Mahmut , Berry, Gerald J. , Langenfeld, Hannah E., Hanson, Andrew C. , Crowson, Cynthia S. , Bois, Melanie C. , Sato, Yuki , Le, Kevin , Weyand, Cornelia M. , Kaymakci, Mahmut S , Le, Kevin-Phu C , Warrington, Kenneth J , Berry, Gerald J , Schaff, Hartzell V. , Le, Kevin-Phu C, Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Rheumatology | July 18, 2024 | Volume: 63 | Issue: 12 | Pages: 3289-3296

10.1093/rheumatology/keae373 | PMID 39024049 Get It

Abstract Objectives To examine the clinicopathologic features of patients with polymyalgia rheumatica (PMR) who had thoracic aorta repair surgery. Findings were compared with those of a cohort of patients with giant cell arteritis (GCA) requiring thoracic aorta repair. Methods All patients evaluated at Mayo Clinic in Rochester, MN, with Current Procedural Terminology (CPT) codes for thoracic aorta repair surgery between 2000–2021 were identified. All patients were screened for prior PMR diagnosis. Patients with PMR and no signs of GCA were categorized as clinically isolated PMR. The medical records of all patients were manually reviewed, and pathologists re-examined all the aortic tissues. Results Of the 4621 patients with at least one CPT code for thoracic aorta repair surgery, 43 patients were diagnosed with clinically isolated PMR before the surgery. Detailed histopathological examination of the aortic tissues revealed active inflammation in 30/43 (70%) patients after a median (IQR) of 10.0 (4.7–13.3) years from the PMR diagnosis. When compared with aortic tissue from patients with a prior diagnosis of GCA, the aorta of patients with PMR had more severe inflammation (Grade 3: 15/30 [50%] vs 5/34 [15%], P = 0.002). Patients with PMR and thoracic aorta repair may experience a 40% increased risk of mortality compared with the general population, but this did not reach statistical significance (standardized mortality ratio: 1.40; 95% CI: 0.91–2.07). Conclusions Some patients with PMR have subclinical aortic inflammation that is detectable many years after initial diagnosis and may contribute to the development of aortic aneurysm.
Molecular Analysis of Persistent and Recurrent Barrett's Esophagus in the Setting of Endoscopic Therapy
Kumar, Aarti , Rara, Marianne , Wen, Kwun Wah , Grady, William M., Chak, Amitabh , Iyer, Prasad G. , Rustgi, Anil K. , Rubenstein, Joel H. , Liu, Yue , Kresty, Laura A. , Westerhoff, Maria , Kwon, Richard S. , Wamsteker, Erik, Wang, Tom, Berry, Lynne D. , Shaheen, Nicholas J. , Wang, Kenneth K, Stachler, Matthew D , Yu, Ming , Wang, Timothy C. , Canto, Marcia Irene , Abrams, Julian A

Mayo Clinic

Clinical and Translational Gastroenterology | July 15, 2024 | Volume: 15 | Issue: 8 | Pages: e00751

10.14309/ctg.0000000000000751 | PMID 39007490 Get It

INTRODUCTION: Early neoplastic progression of Barrett's esophagus (BE) is often treated with endoscopic therapy. Although effective, some patients are refractory to therapy or recur after apparent eradication of the BE. The goal of this study was to determine whether genomic alterations within the treated BE may be associated with persistent or recurrent disease. METHODS: We performed DNA sequencing on pre-treatment esophageal samples from 45 patients who were successfully treated by endoscopic therapy and did not recur as well as pre-treatment and post-treatment samples from 40 patients who had persistent neoplasia and 21 patients who had recurrent neoplasia. The genomic alterations were compared between groups. RESULTS: The genomic landscape was similar between all groups. Patients with persistent disease were more likely to have pre-treatment alterations involving the receptor tyrosine kinase pathway ( P = 0.01), amplifications of oncogenes ( P = 0.01), and deletions of tumor suppressor genes ( P = 0.02). These associations were no longer significant after adjusting for patient age and BE length. More than half of patients with persistent (52.5%) or recurrent (57.2%) disease showed pre-treatment and post-treatment samples that shared at least 50% of their driver mutations. DISCUSSION: Pre-treatment samples were genomically similar between those who responded to endoscopic therapy and those who had persistent or recurrent disease, suggesting there is not a strong genomic component to treatment response. Although it was expected to find shared driver mutations in pre-treatment and post-treatment samples in patients with persistent disease, the finding that an equal number of patients with recurrent disease also showed this relation suggests that many recurrences represent undetected minimal residual disease.
Aseptic Revision Total Hip Arthroplasty Using Modular Fluted Tapered Stems
Carender, Christopher N. , Larson, Dirk R. , Trousdale, Robert T. , Lewallen, David G. , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Larson, Dirk , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | June 27, 2024 | Volume: 106 | Issue: 16 | Pages: 1470-1478

10.2106/jbjs.23.00921 | PMID 38935701 Get It

Background: Modular fluted tapered (MFT) femoral components are frequently utilized in aseptic revision total hip arthroplasties (THAs). However, long-term follow-up has been limited. The purpose of this study was to update our prior series at long-term follow-up, with specific emphasis on implant survivorship, radiographic results, and complications in a large cohort of aseptic revision THAs using MFT stems. Methods: We retrospectively identified 515 aseptic femoral revisions performed with 2 MFT stem designs in the total joint registry of a single tertiary care academic institution from 1999 to 2013. Serial radiographs were reviewed for subsidence of >5 mm. The mean follow-up (and standard deviation) was 10 ± 5 years (range, 2 to 21 years). A competing risk model accounting for death was utilized. Results: The 15-year cumulative incidence of any revision was 12%. There were 57 revisions, 27 of which involved revision of the fluted tapered component (FTC). Dislocation (n = 19), periprosthetic joint infection (n = 15), and aseptic loosening of the FTC (n = 11) were the most common reasons for revision. The 15-year cumulative incidence of any reoperation was 16%. The 15-year cumulative incidences were 6% for any FTC revision and 2% for FTC revision for aseptic loosening. Stem subsidence of >5 mm occurred in 2% of unrevised cases, and all but 1 stem was stable at the most recent follow-up. Conclusions: This large series of MFT stems used in aseptic revision THAs had a 2% incidence of subsequent revision of the FTC for aseptic loosening at 15 years. Dislocation and infection were the most common reasons for any revision. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.